Free tool
FAERS Monitor: Pre-Pen
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 050114 or its brand name (Pre-Pen, Benzylpenicilloyl Polylysine). Reports on generic versions are filed under their own applications.
Reports
35
Serious
11
31% of reports
Hospitalization
1
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pruritus12
- false negative investigation result9
- urticaria6
- anaphylactic reaction4
- skin test positive4
- erythema3
- feeling hot3
- maternal exposure during pregnancy3
- throat tightness3
- drug hypersensitivity2
- dyspnoea2
- exposure during pregnancy2
- peripheral swelling2
- rash2
- skin test negative2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 5 |
| 2019 | 6 |
| 2020 | 7 |
| 2021 | 5 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 1 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,124 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| skin test negative | 2 | 12152.5 | 3118.8 | 13,398 |
| false negative investigation resultSignal | 9 | 7801.0 | 4420.5 | 61,808 |
| skin test positiveSignal | 4 | 2590.1 | 1027.5 | 7,891 |
| throat tightnessSignal | 3 | 66.7 | 22.6 | 134 |
| anaphylactic reactionSignal | 4 | 43.5 | 17.3 | 127 |
| feeling hotSignal | 3 | 29.4 | 10.0 | 57 |
| urticariaSignal | 6 | 21.5 | 10.4 | 99 |
| maternal exposure during pregnancySignal | 3 | 20.2 | 6.9 | 37 |
| exposure during pregnancy | 2 | 19.3 | 5.0 | 19 |
| pruritusSignal | 12 | 18.8 | 11.9 | 188 |
| erythemaSignal | 3 | 8.8 | 3.0 | 14 |
| peripheral swelling | 2 | 7.8 | 2.0 | 6 |
| drug hypersensitivity | 2 | 6.2 | 1.6 | 4 |
| rash | 2 | 2.8 | 0.7 | 1 |
| dyspnoea | 2 | 2.1 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.